局限性前列腺癌DNA修复基因突变患病率与临床病理特征的关联
结果显示Gleason分级分组≥3和病理T3/T4期患者的DNA修复基因突变(尤其是BRCA1/2或ATM)患病率显著更高,而临床T分期和淋巴结分期无差异。
要点
- Gleason分级分组≥3者任何DNA修复基因突变率10.3%,低于1-2级的5.0%,OR 2.2。
- 病理T3/T4期患者任何DNA修复基因突变率13.0%,pT2期为5.5%,OR 2.6。
- Gleason≥3且临床T≥cT3者中21.3%有任何DNA修复基因突变,11.7%有ATM/BRCA1/2突变。
核心结论
- 致病性DNA修复基因改变在晚期肿瘤分期和较高Gleason分级分组患者中富集,在Gleason分级分组≥3且临床分期≥cT3者中富集程度最高。
研究设计与样本
- 研究纳入TCGA验证数据集(n=333)和Nature Genetics数据集(n=377)的局限性前列腺腺癌肿瘤DNA测序信息。
- 分析的HRR基因包括ATM、BRCA1/2、CDK12、CHEK1/2、FANCA、FANCD2、FANCL、GEN1、NBN、PALB2、RAD51和RAD51C。
- 按Gleason分级分组、临床T分期、病理T分期和病理N分期报告致病性DNA修复突变比例,用比值比和Fisher精确检验比较组间比例。
主要发现
- Gleason分级分组≥3者任何DNA修复基因突变率为10.3%,分级分组1-2者为5.0%,OR 2.2(95%CI 1.2-4.2)。
- Gleason分级分组≥3者BRCA1/2或ATM突变率为7.0%,分级分组1-2者为2.7%,OR 2.7(95%CI 1.3-6.6)。
- 病理T3/T4期任何DNA修复基因突变率为13.0%,pT2期为5.5%,OR 2.6(95%CI 1.3-6.6)。
- 病理T3/T4期BRCA1/2或ATM突变率为9.5%,pT2期为3.1%,OR 3.2(95%CI 1.2-11.3)。
- 临床T分期或淋巴结分期组间无差异;Gleason分级分组≥3且临床分期≥cT3者中21.3%有任何DNA修复基因突变,11.7%有ATM/BRCA1/2突变。
关键数值与推荐
- Gleason分级分组≥3与任何DNA修复基因突变OR 2.2(95%CI 1.2-4.2),与BRCA1/2或ATM突变OR 2.7(95%CI 1.3-6.6)。
- 病理T3/T4期与任何DNA修复基因突变OR 2.6(95%CI 1.3-6.6),与BRCA1/2或ATM突变OR 3.2(95%CI 1.2-11.3)。
- Gleason分级分组≥3且临床分期≥cT3者中任何DNA修复基因突变率21.3%,ATM/BRCA1/2突变率11.7%。
临床怎么用
- 该信息可用于指导新辅助/辅助治疗背景下基因组靶向临床试验的入组标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: DNA repair gene mutations are present in 8-10% of localized prostate cancers. It is unknown whether this is influenced by clinicopathologic factors. METHODS: We interrogated localized prostate adenocarcinomas with tumor DNA sequencing information from the TCGA validated (n = 333) and Nature Genetics (n = 377) datasets. Homologous recombination repair genes included in our analysis were: ATM, BRCA1/2, CDK12, CHEK1/2, FANCA, FANCD2, FANCL, GEN1, NBN, PALB2, RAD51, and RAD51C. Proportions of cases with pathogenic DNA repair mutations (and in ATM/BRCA1/2 specifically) were reported by Gleason grade group, clinical T, pathologic T, and pathologic N stage. Odds ratios and Fisher's exact tests were used to compare proportions between categories. RESULTS: Patients with Gleason grade groups 3 and higher were 2.2 times more likely to harbor any DNA repair mutation (95% CI: 1.2-4.2; 10.3% versus 5.0%) and were 2.7 times more likely to have BRCA1/2 or ATM mutations (95% CI: 1.3-6.6; 7.0% versus 2.7%) compared to those in Gleason grade groups 1-2. Patients with pathologic T3 and T4 stage (pT3/pT4) were 2.6 times more likely to have any DNA repair mutation (95% CI: 1.3-6.6; 13.0% versus 5.5%) and were 3.2 times more likely to have BRCA1/2 or ATM mutations (95% CI: 1.2-11.3; 9.5% versus 3.1%) compared to those with pT2 disease. There was no difference by clinical tumor or nodal stage. Among men with Gleason grade group ≥ 3 and clinical stage ≥ cT3, 21.3% (1 in 5) had a DNA repair mutation in any gene and 11.7% (1 in 9) had a mutation in ATM/BRCA1/2. CONCLUSIONS: The prevalence of pathogenic DNA repair gene alterations is enriched in men with advanced tumor stages and higher Gleason grade groups, with maximal enrichment observed in those with Gleason grade group ≥ 3 and clinical stage ≥ cT3 disease. This information can be used to guide eligibility criteria for genomically targeted clinical trials in the neoadjuvant/adjuvant settings.
引用
- Marshall CH, Fu W, Wang H, et al. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis. 2018. PMID: 30171229. doi:10.1038/s41391-018-0086-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。